Search the Newsreel

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:STLN

The Oncology Institute, Inc. (NASDAQ: STLN) generated $502.73 million in revenue last year, with its Dispensary segment being the top performer, contributing $269.18 million. The majority of its revenue, $502.73 million, originated from the United States. This indicates a strong domestic market for the …

Stock Radar: Concord Biotech stock showing signs of rebound after falling over 20% from highs; time to buy

Top Healthcare Stocks to Watch: Why Is OncoSil Medical (ASX:OSL) in Focus?

Behind Concord Healthcare (2453.HK)'s Positive Profit Alert: Gross Profit Surges More Than 160-Fold as Proton Therapy Enters a New Phase of Scalable Growth

Concord Healthcare (2453.HK) has issued a positive profit alert, projecting a significant increase in gross profit for the first half of 2026, surging over 160-fold year-on-year. This remarkable growth is attributed to its proton therapy infrastructure entering a commercialization stage, with the Guangzhou Concord …

ETFs Investing in BridgeBio Oncology Therapeutics, Inc. Stocks

This article lists several ETFs that hold BridgeBio Oncology Therapeutics, Inc. (BBOT) stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price change, and NAV total return. The ETFs highlighted primarily focus on the healthcare and biotechnology sectors, offering …

ALX Oncology (ALXO) Projected to Post Earnings on Tuesday

ALX Oncology (NASDAQ:ALXO) is expected to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.15 per share. The company previously missed Q1 estimates, reporting a $0.17 per share loss. ALXO shares recently saw a …

Price to earnings forward of CG Oncology, Inc. – NASDAQ:CGON

This article provides the "Price to earnings forward" metric for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point displayed within a larger financial analysis platform. The specific value and change percentage are indicated as data fields.

Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company

Wells Fargo & Company has upgraded Pyxis Oncology (NASDAQ:PYXS) to a "strong-buy" rating. Despite the upgrade, the company reported a quarterly EPS of -$0.37, missing analyst estimates. Institutional investors and hedge funds currently hold 39.07% of the company's stock, which has an average analyst …

Vivo Capital LLC Buys Shares of 3,184,713 ALX Oncology Holdings Inc. $ALXO

Vivo Capital LLC recently purchased over 3.18 million shares of ALX Oncology Holdings Inc. (ALXO) for approximately $6.4 million, representing 2.37% of the company. Other institutional investors have also increased their stakes in ALXO, with institutional investors and hedge funds collectively owning 97.97% of …

Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN

This article focuses solely on "Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN". It provides the stock symbol STLN, identifies it as being listed on the Nasdaq Stock Market, and categorizes the company under Health Services / Medical/Nursing Services. The content is …

Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Champions Oncology (NASDAQ:CSBR) saw its stock price fall below its 200-day moving average to $5.76, amidst a downgrade from Weiss Ratings to "sell (E+)." Despite beating quarterly earnings expectations with $0.01 EPS against an anticipated $0.05 loss and revenues of $13.84 million, the company …

Alphamab Oncology Announces Acceptance of NDA for Anbenitamab as Neoadjuvant Treatment for Her2+ Breast Cancer by the NMPA

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $7.50. The stock is currently trading near its 12-month low, and several firms have recently downgraded it. Despite the negative analyst sentiment and a missed …

The Oncology Institute, Inc. will Change its Ticker to STLN from TOI

The Oncology Institute, Inc. announced that its stock ticker symbol on the Nasdaq Capital Market will change from TOI to STLN, effective August 4, 2026. This change follows the company's recent name change to Starling Oncology, Inc.

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing

This article analyzes Kura Oncology Inc. (KURA) for rotational strategy timing, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, with entry points, targets, and stop losses derived from AI models. …

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc. The company, which manages community-based oncology practices across 86 clinic locations in five states, continues to provide medical oncology services, including physician services, infusion, radiation, and clinical trials. This name change …

Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com

Wells Fargo has initiated coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with an overweight rating and a price target of $12.00, citing the potential of its MICVO treatment for head and neck squamous cell carcinoma. Despite a recent nine percent decline, the stock has seen …

Concorde International Group Ltd Revenue Breakdown – NASDAQ:CIGL

Concorde International Group Ltd (NASDAQ:CIGL) reported its revenue breakdown, highlighting Singapore as its largest contributor. The company generated $12.48 million USD from Singapore last year, an increase from $10.49 million USD the prior year. The breakdown shows revenue by source and by country.

Wells Fargo Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12

Wells Fargo has initiated coverage on Pyxis Oncology (PYXS.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This initiation suggests a positive outlook from Wells Fargo regarding Pyxis Oncology's future performance.

The Oncology Institute Rebrands as Starling Oncology

The Oncology Institute (TOI), a major value-based oncology group in the U.S., has officially rebranded as Starling Oncology, Inc. The company's stock will now trade on Nasdaq under the new ticker symbol "STLN" starting August 4, 2026. This rebrand signifies the company's growth and …

Aktis Oncology (AKTS) Expected to Release Earnings on Monday

CIGL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Concorde International Group, Ltd. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Concorde International Group, Ltd. (NASDAQ:CIGL) and its officers. The lawsuit alleges that Concorde made materially false and misleading statements and failed to disclose a fraudulent stock promotion scheme and artificial trading activity …

Price to sales forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

This article provides financial information for The Oncology Institute, Inc. (NASDAQ:TOIIW) focusing on its price to sales forward metric. It appears to be a financial data page from TradingView, displaying market data, financial figures, and general company information for the stock.

Enterprise value to EBITDA forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), focusing on its enterprise value to EBITDA forward. It is presented within the TradingView platform, detailing financial metrics and market data related to the company.

AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue Challenges - Analyst Drop Coverage

ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key Levels - Unusual Put Volume

Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in Focus - Scalping Stock Signals

Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report

This article provides the 10-Q report for Oncolytics Biotech for the first quarter of 2026. The content is a placeholder, indicating that the full financial document is intended to be included.

Price to earnings forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article presents financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), specifically focusing on its price-to-earnings forward metric. It appears to be a stub or a section of a larger financial data platform, providing a snapshot of the company's financial overview without detailed …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – NASDAQ:CSBR

The article focuses on the "Enterprise value to EBITDA forward" financial metric for Champions Oncology, Inc. (NASDAQ: CSBR). It appears to be a financial data snippet or a specific metric page from TradingView, providing financial information for the company. The content lists various sections …

Price to sales forward of Concord Medical Services Holdings Limited – NYSE:CCM

This page provides financial data for Concord Medical Services Holdings Limited (NYSE: CCM), focusing on its forward price-to-sales ratio. The content is primarily a financial data display from TradingView, including market overview, financials, news, community, and technical information for the company.

PYXS Q1 2026 Earnings: Narrow EPS Beat Fails to Stem 7.67% Share Decline - Geographic Revenue Trends

Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC

Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen

Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR

Champions Oncology, Inc. (NASDAQ: CSBR) generated $59.42 million in revenue last year, primarily from its Pharmacology Services segment, which contributed $57.13 million. The majority of this revenue, $59.42 million, came from operations within the United States. This represents an increase from the previous year's …